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Correspondence to: Marı́a José Soler; E-mail: mjsoler01@gmail.com; Joan Torras; E-mail: 15268jta@comb.cat; Twitter handle: @PepaSolerR, Juliana B. Draibe;
E-mail: jbordignon@bellvitgehospital.cat
*These authors contributed equally to this work.
#These authors share credit for senior authorship.
ABSTRACT
Background. The incidence of acute tubulointerstitial nephritis (ATIN) related to drugs has dramatically increased over
recent years. A new subtype of ATIN, apparently different from classical drug-related ATIN, has emerged that has been
related to the administration of immune checkpoint inhibitors (ICIs). We investigated these differences between ICI-related
ATIN (ICI ATIN) and non-ICI-related ATIN in terms of clinical features, response to treatment with steroids and the
evolution of kidney function.
Methods. A total of 47 patients diagnosed with ATIN from two centres were recruited. Of these, 13 patients presented with
ATIN during ICI treatment and 34 were diagnosed with ATIN attributed to other drugs. The main demographic, clinical and
analytical variables such as gender, age and current medication were recorded. The type of malignancy, oncological
treatment, ICI dose and presence of extrarenal immune-related adverse events were also reviewed. Renal biopsy diagnosis,
time to drug withdrawal and ATIN-specific treatment, as well as laboratory data during follow-up, were also studied.
Results. Patients diagnosed with ICI ATIN presented with lower creatinine (ICI ATIN 3.8 6 1.03 versus classical ATIN
5.98 6 4.15 mg/dL, P¼0.007) at diagnosis and higher urinary leucocyte counts (ICI ATIN 263.2 6 418.04 versus classical ATIN
133.55 6 284.62, P¼0.048) compared with patients with non-ICI-related ATIN. Time from initiation of the culprit drug to
ATIN diagnosis was longer in patients with ICI ATIN than in those with classical ATIN (197.07 6 184.99 versus
114.4 6 352.16 days, P¼0.006). In addition, during follow-up, the slope of decreasing creatinine over time was lower for ICI
ATIN compared with non-ICI-related ATIN.
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Conclusions. In this study, we analysed differences between ICI ATIN and classical ATIN. We found that patients with ICI
ATIN presented with a larger latency period after culprit drug initiation, milder acute kidney injury and slower creatinine
amelioration compared with those with classical ATIN. These results may, in part, be ascribed to potential differences in
the pathological mechanisms involved in ATIN development, suggesting that ICI and classical ATIN may be different
diseases with similar renal histologies.
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INTRODUCTION
The incidence of acute tubulointerstitial nephritis (ATIN) re-
lated to drugs has dramatically increased over recent decades.
Data from the Spanish Registry of Glomerulonephritis have
demonstrated that the diagnosis of biopsy-proven ATIN has in-
creased from 3% to 20% over the last 20 years [1]. ATIN has be-
come the third most common cause of acute kidney injury (AKI)
in hospitalized patients [2]. The main trigger associated with
ATIN development is the use of certain nephritogenic drugs
that are able to induce antigen-initiated cell-mediated injury in
kidney tubule cells. The remaining cases are attributable to au-
toimmune conditions and infections, and a few cases are classi-
fied as idiopathic. Diagnosis is based on histological findings,
mainly tubulointerstitial lymphocytic infiltrates without im-
mune deposits [3]. Early withdrawal of the offending drug and
early treatment with corticosteroids constitute the basis of
treatment of the disease [4].
Over the last decade, a new subtype of ATIN has emerged
that is different from classical drug-related ATIN, which has
been related to the administration of immune checkpoint inhib-
itors (ICIs). This group of drugs has shown promising results in
the treatment of tumours with limited responses to conven-
tional chemotherapeutic treatment such as melanoma, non-
small-cell lung carcinoma, renal cell carcinoma and Hodgkin
lymphoma. ICIs are antibodies directed against programmed
cell death-1 (PD-1), PD-1 ligand 1 (PD-L1) and cytotoxic T lym-
phocyte antigen 4 (CTLA4). The PD-1/PD-L1 and CTLA4 path-
ways control the differentiation of autoreactive T lymphocytes
in order to maintain tolerance to self-antigens [5]. The blockade
of these pathways stimulates the immune response toward
cancer cells that express negative T cell surface ligands, but the
immune response triggered by ICIs may result in immune-
mediated adverse events [6]. The incidence of ICI-induced AKI
varies between 2.2% and 29% [7, 8]. ATIN is the dominant pat-
tern of ICI-induced AKI [7] and is histologically indistinguish-
able from ATIN secondary to other drugs. The exact
mechanisms of ICI-related ATIN (ICI ATIN) are not completely
understood, but there are some clues in the literature. ICI may
promote T cell migration to the kidney, reducing tolerance to
endogenous antigens and initiating an inflammatory response
that could lead to ATIN. ICI could also reactivate exhausted
drug-specific T cells and induce loss of tolerance to other medi-
cations [9]. Interestingly, many cases of ICI ATIN occur in
patients receiving drugs independently associated with ATIN,
such as non-steroidal anti-inflammatory drugs (NSAIDs) or pro-
ton pump inhibitors (PPIs), preceding ICI treatment [10].
Although the clinical characteristics seem to be similar, the
pathogenic mechanisms of ICI ATIN and classical ATIN do not
appear to be the same, which suggests that they may require
different clinical management and confer different prognoses.
To the best of our knowledge, there is no study comparing ICI
ATIN and classical ATIN in terms of clinical presentation, and
response to treatment with steroids and follow-up. Moreover, in
both cases, available data are almost limited to case series.
Thus, the aim of this study is to evaluate differences between
ICI ATIN and non-ICI-related ATIN, to examine clinical features,




All cases of biopsy-proven ATIN between January 2015 and May
2019 at Bellvitge University Hospital and Vall d’Hebron
University Hospital were eligible for the study. Exclusion criteria
were as follows: age <18 years old, ATIN related to autoimmune
conditions and presence of urinary tract infections at the time
of inclusion. All patients were prospectively followed by expert
clinicians in the outpatient clinics of both hospitals. The Ethical
Committee of Bellvitge University Hospital approved the study
protocol (PR143/19).
Biopsies
Two kidney cores were obtained with ultrasound guidance us-
ing a 16-gauge spring-loaded biopsy gun: one for optical micros-
copy (haematoxylin and eosin and saffron, periodic acid–Schiff
and Masson trichrome) and one for immunofluorescence (IF).
Biopsies contained at least one glomerular and one arterial pro-
file, and sufficient tubulointerstitial tissue to grade interstitial
inflammation, tubulitis, interstitial fibrosis and tubular atrophy.
All ATIN diagnoses were confirmed by kidney biopsy reviewed
by the local pathologist. ATIN histopathological diagnosis was
defined by the presence of diffuse interstitial oedema and in-
flammatory cell infiltrate mainly composed of lymphocytes and
eosinophils, tubulitis and fibrosis, with negative IF. The defini-
tion of severity of the tubulointerstitial lesions was made
according to the percentage of tissue affected. Cell infiltration
and atrophy were considered severe when >75% of the tubular
surface was affected. Severe fibrosis was defined when it af-
fected >75% of the renal parenchyma.
Clinical variables
We recorded key demographic, clinical and analytical variables
such as gender, age, ethnicity, comorbidities and current medica-
tion with special emphasis on ICIs, NSAIDs, PPIs, angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers
and antibiotics. Medical records regarding the type of malig-
nancy, oncological treatment, first and last dose of ICI, and pres-
ence of extrarenal immune-related adverse events were also
reviewed. At the time of ATIN onset, serum creatinine level, sedi-
ment findings, proteinuria, urine cytology, serological informa-
tion, renal biopsy diagnosis, time to withdrawal of the offending
drug and specific treatment of ATIN were registered, as well as
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laboratory data during the follow-up period. Baseline kidney
function was defined as the value of serum creatinine 6 months
before ATIN. The evolution of clinical and analytical parameters
was registered during the prospective follow-up of the patients.
Relapse was defined as worsening of kidney function not attribut-
able to other causes together with the presence of compatible uri-
nalysis and inflammation parameters. Normalization of kidney
function was defined as glomerular filtration rate (GFR) >60 mL/
min/1.73 m2 or GFR prior to the ATIN episode.
Statistical analysis
Data were analysed using GraphPad Prism version 6.00
(GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics
Version 20.0 (IBM Corp., Armonk, NY, USA). Results were
expressed as frequencies for categorical variables or as the mean
6 standard deviation for continuous variables. The Kolmogorov–
Smirnov test was applied to determine whether quantitative vari-
ables were normally distributed. For comparison of means of two
groups, a Student’s t-test or Mann–Whitney U test was used
depending on the distribution of the variable. The Chi-square test
was used for qualitative variables. Actuarial survival analysis was




Forty-seven patients diagnosed with ATIN were recruited
according to the inclusion and exclusion criteria of the study. Of
these, 13 patients presented with ATIN during treatment with
an ICI and 34 patients were diagnosed with ATIN attributed to
other drugs. Mean time since diagnosis to end of follow-up was
27.04 6 20.75 months (range 0.5–69).
Table 1 shows the main baseline characteristics of both
cohorts. Patients diagnosed with ICI ATIN presented with lower
creatinine levels and higher urinary leucocyte counts compared
with patients with non-ICI-related ATIN at diagnosis. We did
not find differences in the prevalence of systemic symptoms at
presentation such as fever, arthralgias or rash. We found a ten-
dency towards a more severe tubulointerstitial infiltrate and tu-
bular atrophy, together with lesser fibrosis, in the diagnostic
kidney biopsies of ICI ATIN patients compared with non-ICI-re-
lated ATIN cases, but differences did not reach statistical signif-
icance (see Table 1). The length of treatment with ICIs for
patients who presented with ICI ATIN was 197.07 6 184.99 days.
Regarding neoplasia, malignancies found were: lung (nine
patients), melanoma (three patients) and pancreas (one pa-
tient). Five patients did not receive any oncospecific treatment
before ICI treatment. Three patients received cisplatin before ICI
treatment: one of these three received cisplatin only, one in
combination with docetaxel, and one in combination with eto-
poside, chimeric human/mouse immunoglobulin G1 monoclo-
nal antibody and paclitaxel. Five patients received carboplatin
before ICI treatment: four of these five received carboplatin only
and the other in combination with folate antagonist/antineo-
plastic agent. Finally, one patient received five lines of treat-
ment before initiating ICI treatment, one of which was with
anti-PD-L1 plus an anti-CTLA4.
Among patients treated with ICIs, the most frequently in-
volved drugs were antibodies against PD-1 (61.5%). Nine out of
13 patients in the ICI ATIN group were chronically treated with
PPIs (omeprazole). Three of those nine patients were also
treated with NSAIDs (ibuprofen), while the remaining four
patients did not receive any other drugs that have been classi-
cally associated with ATIN. Regarding patients presenting with
ATIN attributed to other drugs, NSAIDs (29.4%) and fluoroquino-
lones (20.6%) were the most frequent aetiologies. Table 2 sum-
marizes the more probable aetiologies of ATIN in both cohorts.
Table 1. Baseline characteristics of the population
Clinical data ICI ATIN Non-ICI-related ATIN P-value
n¼ 13 n¼ 34
Age (years) 71 6 8.48 63.09 6 16.12 0.101
Sex: male/female (% patients) 69.24/30.76 50/50 0.453
Hypertension (% patients) 53.84 64.7 0.52
Diabetes (% patients) 23.08 23.53 1
Creatinine prior to ATIN (mg/dL) 1.01 6 0.32 0.96 6 0.37 0.69
Creatinine at diagnosis (mg/dL) 3.8 6 1.033 5.98 6 4.15 0.007
C-reactive protein at diagnosis (mg/mL) 59.95 6 95.74 37.1 6 67.22 0.408
Blood eosinophil count at diagnosis ( 10e9/L) 0.2531 0.3424 0.394
Proteinuria at diagnosis (mg/g creatinine) 467.12 6 183.73 1086 6 1558.95 0.808
Haematuria at diagnosis (% patients) 66.7 37.5 0.084
Urinary leucocyte count at diagnosis (count/mL) 263.20 6 418.04 133.55 6 284.62 0.048
Systemic symptoms at presentation (% patients)
Rash 0 11.8 0.564
Fever 30.8 22.1 0.7
Arthralgia 15.4 5.9 0.304
Histologic features in diagnostic kidney biopsy (% patients)
Severe inflammatory infiltrate 46.2 35.3 0.516
Severe tubular atrophy 15.4 11.8 0.086
Severe interstitial fibrosis 0 8.8 0.544
Presence of granuloma 8.3 8.8 1
Presence of eosinophilic infiltrate 69.2 88.2 0.35
Presence of plasma cells infiltrate 33.3 41.2 0.739
Data are presented as mean 6 standard deviation unless otherwise indicated.
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Follow-up and evolution of ATIN
Creatinine. AKI was less severe in ICI ATIN patients compared
with non-ICI-related ATIN patients. At the time of diagnosis,
creatinine levels were significantly lower in ICI ATIN patients
(3.8 6 1.03 versus 5.98 6 4.15 mg/dL, P¼ 0.007). Peak creatinine
levels reached during AKI were also lower in ICI ATIN compared
with non-ICI-related ATIN patients (4.19 6 1.43 versus
6.22 6 4.63 mg/dL, P¼ 0.034). Time from initiation of the culprit
drug to the ATIN diagnostic biopsy was longer in ICI ATIN com-
pared with non-ICI-related ATIN patients (197.07 6 184.99 ver-
sus 114.4 6 352.16 days, P¼ 0.006).
During follow-up, the slope of decreasing creatinine over
time was lower in ICI ATIN compared with non-ICI-related
patients. Creatinine decrease (D creatinine) was lower from
baseline to Month 1, from baseline to Month 3, and from base-
line to Month 6 in ICI ATIN patients compared with non-ICI-re-
lated ATIN patients. (P ¼ 0.023, 0.014 and 0.004, respectively).
Figure 1A shows mean serum creatinine evolution during the
first year after diagnosis of ATIN in both cohorts.
We registered the time elapsed since the initiation of ATIN
treatment with prednisone to the normalization of kidney
function (defined as GFR >60 mL/min/1.73 m2 or GFR prior to the
ATIN episode). We noticed that there tended to be slower renal
function recovery in ICI ATIN compared with non-ICI-related
ATIN patients, but differences did not reach statistical signifi-
cance. A similar percentage of patients achieved normal renal
function at the end of follow-up (44.1% versus 30.8% of patients
in the ICI ATIN versus the non-ICI-related ATIN cohort of
patients, P¼ 0.4). Of note, a year after prednisone initiation, the
percentage of patients who showed kidney function recovery
remained stable during the rest of the follow-up period (see
Figure 2).
Proteinuria. We did not find differences in proteinuria at
diagnosis between ICI ATIN and non-ICI-related ATIN
patients (P¼ 0.808). Despite this, the amelioration of protein-
uria (D proteinuria) was lower in ICI ATIN compared with
non-ICI-related ATIN patients. Decrease in proteinuria was
lower in ICI ATIN patients between baseline and Month 1,
and between baseline and Month 3, compared with non-ICI
related patients (P ¼ 0.015 and 0.033, respectively) (see
Figure 1B).
Table 2. Aetiology of ATIN in the cohorts of ICI ATIN and non-ICI-related patients
ICI related ATIN (n¼ 13) Non-ICI related ATIN (n¼34)
Drug % cases Drug % cases
Anti-PD-1 61.5 NSAIDs 29.4
Anti-PD-L1 23.1 Fluoroquinolones 20.6
Anti-PD-1þanti-CTLA4 7.7 b-Lactams 8.8
Anti-PD-L1þanti-CTLA4 7.7 PPIs 2.9
Others 38.2
The non-ICI-related ATIN cases were attributed to: sitagliptin, rifampicin, repaglinide, fosfomycin, lenalidomide, cocaine, vandetanib and cobimetinib.
FIGURE 1: Evolution of creatinine (A), proteinuria (B), leucocyturia (C), eosinophil count (D) and C-reactive protein (E) after 5 months to 1 year of follow-up.
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Urinary leucocyte count. Urinary leucocyte count was higher in
ICI ATIN compared with non-ICI-related ATIN patients at diag-
nosis (P¼ 0.048). Both cohorts presented similar outcomes of
this parameter (see Figure 1C).
Blood eosinophil count. Mean blood eosinophil count remained
lower in ICI ATIN patients compared with non-ICI-related ATIN
patients during the follow-up period, but differences did not
reach statistical significance (see Figure 1D).
Serum C-reactive protein levels. Mean serum C-reactive protein
levels were higher in ICI ATIN patients compared with non-ICI-
related ATIN patients from Month 3, although differences did
not reach statistical significance at the time points evaluated
(see Figure 1E).
Treatment of the ATIN episode
The offending drug was withdrawn in all cases. All patients
were treated with prednisone. Three out of 13 patients in the ICI
ATIN cohort and 3/34 patients in the non-ICI-related ATIN co-
hort received intravenous methylprednisolone pulses at diag-
nosis. Three out of 34 patients in the non-ICI-related cohort
received mycophenolate mofetil compared with 0/13 patients in
the ICI ATIN cohort.
Time to initiation of treatment with steroids was inferior in
ICI ATIN compared with non-ICI-related ATIN cases (P¼ 0.027).
The dosing and schedule of prednisone was similar for ICI ATIN
and non-ICI-related ATIN patients. The prednisone cumulative
dose was similar between patients in the two cohorts
(P¼ 0.883), as was the duration of the treatment (P¼ 0.932).
There were no differences in the prednisone cumulative dose
during the first 3 months of treatment. Time since diagnosis to
prednisone initiation was similar in both cohorts (P¼ 0.387).
Table 3 compares the dosing of prednisone in the two cohorts.
Relapses
Relapse rate did not differ between the two cohorts of ATIN
patients (P¼ 0.334). Three cases of relapse were identified dur-
ing follow-up in each cohort. The main characteristics of
patients who relapsed are displayed in Table 4.
DISCUSSION
Herein, we present 13 biopsy-proven cases of ATIN in the set-
ting of treatment with ICIs, and we compare their baseline char-
acteristics and evolution with 34 cases of ATIN related to other
drugs. To the best of our knowledge, this is the largest case se-
ries of ICI-related ATIN reported to date and the only published
clinical comparison that has attempted to find differences in
features compared with other forms of nephritis.
ICI ATIN patients in our cohort presented with milder forms
of AKI compared with non-ICI-related cases. In agreement with
this finding, other case series in the literature have also
reported slight increases in creatinine in patients with ICI AKI.
In the case series published by Cortazar et al. [7], 12 patients
treated with ICIs presenting with ATIN showed a mean peak
creatinine level of 4.5 mg/dL, similar to the peak creatinine no-
ticed in our cohort (4.15 mg/dL). Cassol et al. [11] published a re-
port of nine cases of ICI ATIN with peak creatinine levels
between 1.4 and 4.3 mg/dL. In concordance, Shirali et al.
reported six cases of ICI ATIN with a peak creatinine ranging be-
tween 1.8 and 2.3 mg/dL in five cases, and a peak creatinine of
5.5 mg/dL in the remaining one [10]. Only in one case series of
five patients with ATIN related to ICI treatment [12] did the
authors observe higher peak creatinine levels between 4.8 and
7.8 mg/dL. Urinary leucocyte counts at diagnosis were signifi-
cantly higher in ICI ATIN compared with non-ICI-related ATIN
patients.
Although a similar proportion of patients recovered baseline
kidney function at the end of follow-up, renal function recovery
was slower in ICI ATIN compared with non-ICI-related ATIN
patients. This is reflected by the differences in D creatinine be-
tween diagnosis and Months 1, 3 and 6, which were statistically
lower in ICI ATIN compared with non-ICI-related ATIN patients.
The same pattern was followed by D proteinuria followed dur-
ing the first 3 months. Although differences did not reach statis-
tical significance, slower recovery of the kidney function of
ICI-treated patients was observed via Kaplan–Meier survival
analysis curves. One could hypothesize that slower renal recov-
ery after ICI discontinuation may be ascribed to the longer half-
life of ICIs, ranging between 20 and 25 days [13], and the fact
that this class of drugs can remain bound to lymphocytes for up
FIGURE 2: Time from ATIN diagnosis to renal function recovery in both studied
ATIN groups.
Table 3. Treatment comparison between patients with ICI ATIN and non-ICI-related ATIN patients
Steroid treatment ICI ATIN Non-ICI-related ATIN P-value
Time since ATIN diagnosis to steroid initiation (days) 9.92 6 17.57 2.52 6 6.15 0.027
Initial methylprednisolone bolus administration (% patients) 25 8.82 0.178
Prednisone cumulative dose (g) 9.39 6 21.92 3.59 6 2.78 0.883
Months of prednisone treatment 5 6 3.32 9 6 9.87 0.932
Prednisone cumulative dose per month of treatment (g/month) 1.31 6 1.96 0.62 6 0.407 0.132
Prednisone cumulative dose at Month 1 (mg) 1564.38 6 511.28 1456 6 637 0.597
Prednisone cumulative dose at Month 2 (mg) 2270.92 6 693.67 2115.5 6 741.56 0.537
Prednisone cumulative dose at Month 3 (mg) 2735.73 6 1026.31 2454.30 6 1070.19 0.959
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to 57 days [14]. Other case series have described variable kidney
function normalization rates ranging from as few as 2/12
patients [7] to almost all patients in a case series (5/6 patients)
[10]. These differences were not related to ATIN treatment. All
patients were treated with steroids and there were no differen-
ces in prednisone cumulative doses and the duration of treat-
ment. Time to steroid initiation has been proposed to be one of
the main factors that determines the outcome of classical ATIN
[15]. In our study, the initiation of steroid treatment after ATIN
was delayed in non-ICI-related cases. However, this differential
delay did not influence the outcome: we did not find differences
in renal function at the end of the follow-up period.
The period of time between offending drug initiation and
ATIN diagnosis was longer in ICI ATIN compared with non-ICI-
related cases. Long latency periods until ATIN development in
patients treated with ICIs have been previously reported [7, 14].
This may, in part, be explained by differential pathological
mechanisms of ATIN development. It has been demonstrated
previously that classical drug-induced ATIN is an allergic drug
hypersensitivity reaction mediated by T lymphocytes. However
the pathological mechanisms of ICI ATIN are unknown. It has
been hypothesized that the use of an ICI breaks down immune
tolerance to antigens that would not otherwise be nephritogenic
[10]. In agreement, Koda et al. [16] performed a lymphocyte stim-
ulation test in a nivolumab-associated ATIN patient and con-
firmed drug-induced (lansoprazole) lymphocyte stimulation,
although it had been used safely for a long time before the initi-
ation of anti-PD-1 therapy. Further research focusing on the im-
plicated molecular mechanisms is necessary to confirm this
hypothesis. Longer latency periods together with strict monitor-
ing of patients who undergo ICI therapy may explain the lower
creatinine levels of these patients at the moment of diagnosis
compared with the faster development of ATIN in the setting of
other drugs in individuals who are not monitored.
Although differences did not reach statistical significance,
ICI ATIN patients showed more inflammatory infiltrates and
less fibrosis. We hypothesize that this may be in line with the
finding of lower peak creatinine levels and, possibly, the early
diagnosis of such patients compared with those with non-ICI-
related ATIN. Another difference between ICI and non-ICI-re-
lated ATIN reported in the literature is the occurrence of a flare
after drug re-exposure. Recurrence of classical drug-induced
ATIN upon re-exposure to the offending drug has been widely
described [3]. In contrast, Cortazar et al. [17] recently reported a
low prevalence of recurrence of ATIN upon ICI re-challenge af-
ter successful treatment of the first episode.
The observational, retrospective nature of the study consti-
tutes its main limitation. Although differences in treatment of
ATIN episodes were not noticed between the two cohorts, stan-
dardization of the prednisone schedule would allow stronger
conclusions about differences in ATIN evolution between ICI
and non-ICI-related ATIN.
CONCLUSION
In this study, we present the largest case series of ICI ATIN to
date and, to our knowledge, the first published comparison with
non-ICI-related ATIN cases. We observe that ICI ATIN patients
manifest a longer latency period after offending drug initiation,
milder AKI and slower creatinine amelioration compared with
ATIN in the setting of another drug treatments. This differential
evolution may be ascribed to potential differences in the patho-
logical mechanisms behind ATIN development. Further investi-
gation and cumulative experience are required to determine
whether the differences between classical ATIN and ICI ATIN
are enough for them to be considered as two different diseases.
ACKNOWLEDGEMENTS
We gratefully acknowledge the support of FIS/Fondos FEDER
(REDinREN RD016/0009).
CONFLICT OF INTEREST STATEMENT
None declared.









relapse (mg) Relapse cause
Serum creati-
nine at re-
lapse (mg/dL) Relapse treatment Evolution
M/71/anti-PD-1 8 4075 Offending drug re-
initiation
2.07 Prednisone 30 mg/day Normalization of
serum
creatinine
M/81/anti-PD-1 4 2425 Ciprofloxacin initiation
plus decrease in pred-
nisone dose
3.02 Prednisone 30 mg/day Normalization of
serum
creatinine
F/83/anti-PD-1 3 2572.5 Prednisone withdrawal 10.59 Methylprednisolone





M/77/NSAIDs 15 3750 Prednisone withdrawal 2.51 Prednisone 40 mg/day Stabilization—
creatinine
1.5 mg/dL





5 2060 Unknown 2.03 Prednisone 15 mg/day Stabilization—
creatinine
1.5 mg/dL
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